Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jan-Dec:16:1479973119869334.
doi: 10.1177/1479973119869334.

Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?

Affiliations
Observational Study

Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?

Sandra Cuerpo et al. Chron Respir Dis. 2019 Jan-Dec.

Abstract

Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is defined as a sudden acceleration of the disease with the appearance of pulmonary infiltrates superimposed on the characteristic pattern of IPF that leads to a significant decline in lung function. It has high in-hospital mortality rates, despite medical treatment with systematic steroids. We sought to investigate whether there were in-hospital mortality differences according to clinical stratification (AE, suspected AE, or AE of known cause) and/or treatment with systemic steroids. We reviewed the clinical characteristics and outcomes of patients with IPF admitted to our hospital during the years 2003-2014 due to a worsening of their clinical status. We identified 50 IPF patients, 9 with AE (18%), 12 with suspected exacerbation (24%), and 29 with AE of known cause (58%), mostly respiratory infections. In-hospital mortality was similar in the three groups (33% vs. 17% vs. 34%, respectively). Likewise, we did not find differences between them with respect to the use of systemic steroids (length of treatment duration or total dose). Nevertheless, there was an independent association between in-hospital mortality and high average daily steroid dose. We did not observe significant differences in prognosis or use of systemic steroids according to current diagnostic stratification groups in patients hospitalized because of an exacerbation of IPF.

Keywords: Idiopathic pulmonary fibrosis; acute exacerbation; corticosteroid therapy; usual interstitial pneumonia.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Schematic representation of the studied population. The main reasons for excluding patients were planned hospital admission without worsening of the respiratory symptoms (n = 21), patients with severe immunosuppression resulting from bone marrow transplantation or solid organ transplant (n = 2), severe hematological diseases (n = 6), and active malign neoplasm (n = 5). ICD: International Classification of Diseases.
Figure 2.
Figure 2.
Survival analysis for the three definition groups. (a) Survival analysis comparing AE, SAE and AEKE (b) Survival analysis comparing idiopathic excerbation (combined AE/SAE patients) and AEKE. AE: acute exacerbation; SAE: suspected acute exacerbation; AEKE: acute exacerbation of known etiology.
Figure 3.
Figure 3.
(a) ROC curves of daily corticosteroids dose in relation to in-hospital mortality and (b) survival analysis between patients with high and low doses of corticosteroids. ROC: receiver operating characteristics.

References

    1. Raghu G, Weycker D, Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816. - PubMed
    1. Raghu G, Collard HR, Egan JJ. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. - PMC - PubMed
    1. Collard HR, Moore BB, Flaherty KR. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636–643. - PMC - PubMed
    1. Song JW, Hong SB, Lim CM. et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356–363. - PubMed
    1. Collard HR, Yow E, Richeldi L. et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013; 14: 73. - PMC - PubMed

Publication types

Substances